Auriga Reiterates a 'Buy' on Myriad Genetics (MYGN); Raising PT on Strong Results
Get Alerts MYGN Hot Sheet
Price: $21.40 --0%
Rating Summary:
8 Buy, 15 Hold, 5 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 10 | Down: 9 | New: 10
Rating Summary:
8 Buy, 15 Hold, 5 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 10 | Down: 9 | New: 10
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Myriad Genetics (NASDAQ: MYGN) price target raised to $31.00.
Analyst, Peter McDonald, said, "MYGN reported F3Q12 revenue of $130MM, well ahead of our $119MM estimate and consensus of $115MM. EPS of $0.34 also came in ahead of both consensus ($0.31) and our estimate ($0.32). BRACAnalysis grew 17% Y/Y, as MYGN continued investment in its sales force and continued uptake in new settings boosted demand. Colaris/Colaris AP revenue grew 51% Y/Y as the addition of the fourth gene (PMS2) and an expanded sales force continue to enhance uptake. MYGN's other tests (six in all) generated $6MM in revenue (+34%). MYGN once again increased FY12 revenue and EPS guidance. Overall, MYGN continues to put up very solid results and is executing well on its plans to diversify its product portfolio. We expect continued uptake of new tests, European sales ramp, and news flow around Prolaris to drive interest in MYGN shares in FY13."
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $25.97 yesterday.
Analyst, Peter McDonald, said, "MYGN reported F3Q12 revenue of $130MM, well ahead of our $119MM estimate and consensus of $115MM. EPS of $0.34 also came in ahead of both consensus ($0.31) and our estimate ($0.32). BRACAnalysis grew 17% Y/Y, as MYGN continued investment in its sales force and continued uptake in new settings boosted demand. Colaris/Colaris AP revenue grew 51% Y/Y as the addition of the fourth gene (PMS2) and an expanded sales force continue to enhance uptake. MYGN's other tests (six in all) generated $6MM in revenue (+34%). MYGN once again increased FY12 revenue and EPS guidance. Overall, MYGN continues to put up very solid results and is executing well on its plans to diversify its product portfolio. We expect continued uptake of new tests, European sales ramp, and news flow around Prolaris to drive interest in MYGN shares in FY13."
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $25.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Xinte Energy Co Ltd (1799:HK) to Hold, 'cost cutting efforts likely to keep away from loss making'
- Guangdong Investment Ltd (270:HK) PT Lowered to HK$4 at HSBC
- Cellectar Biosciences (CLRB) PT Raised to $12 at Oppenheimer
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!